KR20010012505A - 양성 전립선 과형성의 치료에 유용한 아릴 치환된 피페라진 - Google Patents
양성 전립선 과형성의 치료에 유용한 아릴 치환된 피페라진 Download PDFInfo
- Publication number
- KR20010012505A KR20010012505A KR1019997010460A KR19997010460A KR20010012505A KR 20010012505 A KR20010012505 A KR 20010012505A KR 1019997010460 A KR1019997010460 A KR 1019997010460A KR 19997010460 A KR19997010460 A KR 19997010460A KR 20010012505 A KR20010012505 A KR 20010012505A
- Authority
- KR
- South Korea
- Prior art keywords
- treatement
- benign prostatic
- piperazines useful
- arylsubstituted
- hyperlasia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4623697P | 1997-05-12 | 1997-05-12 | |
US60/046,236 | 1997-05-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010012505A true KR20010012505A (ko) | 2001-02-15 |
KR100440755B1 KR100440755B1 (ko) | 2004-07-21 |
Family
ID=21942353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-1999-7010460A KR100440755B1 (ko) | 1997-05-12 | 1998-05-08 | 양성 전립선 과형성의 치료에 유용한 아릴 치환된 피페라진 |
Country Status (28)
Country | Link |
---|---|
US (4) | US6071915A (ko) |
EP (1) | EP0984777B1 (ko) |
JP (1) | JP4189867B2 (ko) |
KR (1) | KR100440755B1 (ko) |
CN (3) | CN1149081C (ko) |
AP (1) | AP1349A (ko) |
AR (1) | AR012686A1 (ko) |
AT (1) | ATE250033T1 (ko) |
AU (1) | AU7366998A (ko) |
BR (1) | BR9809804A (ko) |
CA (1) | CA2289987C (ko) |
CZ (1) | CZ298217B6 (ko) |
DE (1) | DE69818255T2 (ko) |
DK (1) | DK0984777T3 (ko) |
EA (1) | EA001904B1 (ko) |
ES (1) | ES2206928T3 (ko) |
HK (1) | HK1024630A1 (ko) |
HU (1) | HUP0100048A3 (ko) |
IL (1) | IL132836A0 (ko) |
MY (2) | MY127385A (ko) |
NO (1) | NO314144B1 (ko) |
NZ (1) | NZ500992A (ko) |
PL (1) | PL192596B1 (ko) |
PT (1) | PT984777E (ko) |
TR (1) | TR199902971T2 (ko) |
TW (1) | TW512146B (ko) |
WO (1) | WO1998051298A1 (ko) |
ZA (1) | ZA983968B (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2768055A1 (fr) * | 1997-09-11 | 1999-03-12 | Synthelabo | Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie |
EP1346983A3 (en) * | 1998-02-20 | 2003-12-03 | Ortho-Mcneil Pharmaceutical, Inc. | Phthalimido arylpiperazines as alpha 1A receptor antagonists useful in the treatment of benign prostatic hyperplasia |
ZA991319B (en) | 1998-02-20 | 2000-11-20 | Ortho Mcneil Pharm Inc | Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia. |
TW536538B (en) | 1998-02-20 | 2003-06-11 | Ortho Mcneil Pharm Inc | Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia |
US20020082421A1 (en) * | 2000-09-14 | 2002-06-27 | Abdel-Magid Ahmed F. | Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide |
CN1230423C (zh) | 2000-11-30 | 2005-12-07 | 兰贝克赛实验室有限公司 | 可有效用作尿-选择性α1-肾上腺素能受体封阻剂的1,4-双取代的哌嗪衍生物 |
US20090312344A1 (en) * | 2004-05-31 | 2009-12-17 | Mohammad Salman | Arylpiperazine derivatives as adrenergic receptor antagonists |
WO2006092710A1 (en) * | 2005-03-02 | 2006-09-08 | Ranbaxy Laboratories Limited | Metabolites of 2-{3-[4-(2-isopropoxyphenyl) piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-1h-isoindole-1,3-(2h)-dione |
WO2007029156A2 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Isoindoledione derivatives as adrenergic receptor antagonists |
CN102391169B (zh) * | 2011-10-17 | 2015-10-28 | 上海化学试剂研究所 | N-(5-甲氧基-3-吲哚乙基)-4-取代苯基哌嗪-1-乙酰胺的制备方法 |
CN103387531A (zh) * | 2012-05-10 | 2013-11-13 | 广州医学院 | 酰胺类芳基哌嗪衍生物及其制备方法和在抗良性前列腺增生中的应用 |
CN103980195A (zh) * | 2014-04-28 | 2014-08-13 | 广州医科大学 | 酰胺类苯基哌嗪衍生物及其盐与在制备治疗良性前列腺增生症药物中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069336A (en) * | 1976-02-25 | 1978-01-17 | Chemisches Laboratorium Fritz-Walter Lange Gmbh & Co Kg | (2-oxo-pyrrolidines)-acetic hydrazides |
JPS5955878A (ja) | 1982-09-24 | 1984-03-31 | Chugai Pharmaceut Co Ltd | 新規なフエニルピペラジン誘導体 |
WO1984004302A1 (en) * | 1983-04-27 | 1984-11-08 | Byk Gulden Lomberg Chem Fab | Substituted picolinic acids, processes for their preparation, their use and medicaments containing them |
JPS62135464A (ja) * | 1985-12-10 | 1987-06-18 | Nippon Kayaku Co Ltd | フエニルピペラジン誘導体 |
GB8703749D0 (en) | 1987-02-18 | 1987-03-25 | Sandoz Ltd | Piperazinecarboxylic acid |
US5254552A (en) * | 1988-05-24 | 1993-10-19 | American Home Products Corporation | Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity |
SG65570A1 (en) * | 1992-02-25 | 1999-06-22 | Recordati Chem Pharm | Heterobicyclic compounds |
FR2692894B1 (fr) * | 1992-06-24 | 1994-10-14 | Irceba | Aryl-1-(o-alcoxy-phényl-4-pipérazinyl-1)-2, 3- ou 4-alcanols, leur procédé de préparation et leur utilisation pour la préparation de médicaments. |
US5403847A (en) * | 1992-11-13 | 1995-04-04 | Synaptic Pharmaceutical Corporation | Use of α1C specific compounds to treat benign prostatic hyperlasia |
IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
US5688795A (en) * | 1994-11-08 | 1997-11-18 | Syntex (U.S.A.) Inc. | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists |
US5807856A (en) * | 1995-11-15 | 1998-09-15 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonist |
EP0881235A1 (fr) * | 1997-05-26 | 1998-12-02 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Nouveaux ylures de phosphore, leur préparation et leurs utilisations notamment en tant que bases fortes faiblement nucléophiles |
US6063785A (en) * | 1999-02-17 | 2000-05-16 | Ortho-Mcneil Pharmaceutical Inc. | Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia |
TW536538B (en) * | 1998-02-20 | 2003-06-11 | Ortho Mcneil Pharm Inc | Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia |
US6218396B1 (en) * | 1998-02-20 | 2001-04-17 | Orth-Mcneil Pharmaceutical, Inc. | Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia |
-
1998
- 1998-05-08 HU HU0100048A patent/HUP0100048A3/hu unknown
- 1998-05-08 CA CA002289987A patent/CA2289987C/en not_active Expired - Fee Related
- 1998-05-08 DK DK98920950T patent/DK0984777T3/da active
- 1998-05-08 US US09/074,789 patent/US6071915A/en not_active Expired - Lifetime
- 1998-05-08 AT AT98920950T patent/ATE250033T1/de not_active IP Right Cessation
- 1998-05-08 ES ES98920950T patent/ES2206928T3/es not_active Expired - Lifetime
- 1998-05-08 AP APAP/P/1999/001684A patent/AP1349A/en active
- 1998-05-08 DE DE69818255T patent/DE69818255T2/de not_active Expired - Fee Related
- 1998-05-08 PT PT98920950T patent/PT984777E/pt unknown
- 1998-05-08 PL PL342518A patent/PL192596B1/pl not_active IP Right Cessation
- 1998-05-08 NZ NZ500992A patent/NZ500992A/xx unknown
- 1998-05-08 BR BR9809804-7A patent/BR9809804A/pt active Search and Examination
- 1998-05-08 AU AU73669/98A patent/AU7366998A/en not_active Abandoned
- 1998-05-08 EP EP98920950A patent/EP0984777B1/en not_active Expired - Lifetime
- 1998-05-08 TR TR1999/02971T patent/TR199902971T2/xx unknown
- 1998-05-08 KR KR10-1999-7010460A patent/KR100440755B1/ko not_active IP Right Cessation
- 1998-05-08 CN CNB988049112A patent/CN1149081C/zh not_active Expired - Fee Related
- 1998-05-08 WO PCT/US1998/009023 patent/WO1998051298A1/en active IP Right Grant
- 1998-05-08 IL IL13283698A patent/IL132836A0/xx not_active IP Right Cessation
- 1998-05-08 CZ CZ0399799A patent/CZ298217B6/cs not_active IP Right Cessation
- 1998-05-08 EA EA199900928A patent/EA001904B1/ru not_active IP Right Cessation
- 1998-05-08 JP JP54927698A patent/JP4189867B2/ja not_active Expired - Fee Related
- 1998-05-08 CN CNB2003101029013A patent/CN1269807C/zh not_active Expired - Fee Related
- 1998-05-08 CN CNA031070485A patent/CN1515556A/zh active Pending
- 1998-05-09 MY MYPI20041438A patent/MY127385A/en unknown
- 1998-05-09 MY MYPI98002108A patent/MY122095A/en unknown
- 1998-05-11 ZA ZA9803968A patent/ZA983968B/xx unknown
- 1998-05-11 AR ARP980102181A patent/AR012686A1/es active IP Right Grant
- 1998-08-12 TW TW087107253A patent/TW512146B/zh not_active IP Right Cessation
-
1999
- 1999-11-11 NO NO19995518A patent/NO314144B1/no not_active IP Right Cessation
-
2000
- 2000-03-15 US US09/526,224 patent/US6890921B1/en not_active Expired - Lifetime
- 2000-06-12 US US09/591,814 patent/US6593474B1/en not_active Expired - Lifetime
- 2000-06-29 HK HK00103972A patent/HK1024630A1/xx not_active IP Right Cessation
-
2003
- 2003-06-02 US US10/452,255 patent/US20030220493A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL320751A1 (en) | Preparations in the form of power employing melesitose as diluent | |
AU9781998A (en) | Huchordin and uses thereof | |
AU2235395A (en) | Biological markers of benign prostate hyperplasia | |
KR20010012505A (ko) | 양성 전립선 과형성의 치료에 유용한 아릴 치환된 피페라진 | |
AU9166298A (en) | Detergent cosmetic compositions and use | |
AU6548598A (en) | Enhancement of guar solution stability | |
AU1657097A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia | |
IL137954A0 (en) | Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia | |
AU6519198A (en) | Melaninization inhibitor, skin-care preparation, and bath agent | |
AU2160697A (en) | Nsaids in the treatment of pruritus | |
AU8053798A (en) | Tissue plasminogen activator-like protease | |
AU2002300904A1 (en) | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia | |
AU1454199A (en) | Pdgf-mediated microvascular communication and methods of use thereof | |
AU1877497A (en) | Quinoxaline derivatives useful in therapy | |
AUPP263498A0 (en) | Novel therapeutic molecules and uses therefor | |
AU4302497A (en) | Metalocarboxypeptidase inhibitors and derived molecules as antitumoural agents | |
ZA987425B (en) | Phenylethanolaminotetralin derivatives and bronchodilators | |
AU1801499A (en) | Uses of p27 in prostate cancer | |
AU2003204320A1 (en) | Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof | |
GB9602903D0 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
AU6409598A (en) | An improvement in the treatment of wastes | |
AU6458898A (en) | Compositions and use of m-csf-alpha | |
AU681995B3 (en) | Fragrance burner body and fragrance burner | |
AUPP542298A0 (en) | Novel tissue and uses therefor | |
AUPP096197A0 (en) | Novel molecules and uses thereof-iv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20090623 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |